Clinical and histopathologic characteristics of patients with HGBL-NOS (N = 160)
| Variable . | . | . |
|---|---|---|
| Age, median (range), y | 64 | 18-92 |
| Sex, n (%) | ||
| Male | 108 | 67.5% |
| Female | 52 | 32.5% |
| Poor PS, n (%)∗ | 33 | 20.6% |
| Stage, n (%)† | ||
| I or II | 48 | 30.6% |
| III or IV | 109 | 69.4% |
| Undetermined | 3 | |
| >1 extranodal site, n (%) | 66 | 41.3% |
| Bone marrow involvement, n (%)∗ | 39 | 24.4% |
| CNS involvement, n (%) | 11 | 6.9% |
| LDH > ULN, n (%)∗ | 110 | 68.8% |
| LDH > 3 × ULN, n (%)∗ | 37 | 23.1% |
| IPI, n (%) | ||
| Low | 34 | 21.3% |
| Intermediate low | 27 | 16.9% |
| Intermediate high | 42 | 26.3% |
| High | 44 | 27.5% |
| Undetermined | 13 | 8.1% |
| Morphology, n (%) | ||
| Burkitt-like | 72 | 45.0% |
| Blastoid | 38 | 23.8% |
| Unspecified | 50 | 31.3% |
| Cell of origin (based on IHC), n (%)† | ||
| GCB-like | 131 | 82.9% |
| Non-GCB | 27 | 17.1% |
| Undetermined | 2 | |
| CD10 expression, n (%) | ||
| Positive | 123 | 76.9% |
| Negative | 37 | 23.1% |
| BCL6 expression, n (%)† | ||
| Positive | 120 | 80.0% |
| Negative | 30 | 20.0% |
| Not tested | 10 | |
| BCL2 expression, n (%)† | ||
| Positive | 83 | 53.9% |
| Negative | 71 | 46.1% |
| Not tested | 6 | |
| MYC expression, n (%)† | ||
| Positive | 102 | 71.8% |
| Negative | 40 | 28.2% |
| Not tested | 18 | |
| MUM1 expression, n (%)† | ||
| Positive | 60 | 45.5% |
| Negative | 72 | 54.5% |
| Not tested | 28 | |
| Dual MYC and BCL2 expressor, n (%)† | ||
| Yes | 52 | 37.1% |
| No | 88 | 62.9% |
| Undetermined | 20 | |
| CD5 expression, n (%)† | ||
| Positive | 20 | 14.1% |
| Negative | 122 | 85.9% |
| Not tested | 18 | |
| MYC rearrangement, n (%) | ||
| Yes | 44 | 27.5% |
| No | 116 | 72.5% |
| BCL2 rearrangement, n (%)† | ||
| Yes | 17 | 12.7% |
| No | 117 | 87.3% |
| Not tested | 26 | |
| BCL6 rearrangement, n (%)† | ||
| Yes | 15 | 11.2% |
| No | 119 | 88.8% |
| Not tested | 26 | |
| First-line therapy, n (%) | ||
| DA-EPOCH-R | 68 | 42.5% |
| R-CHOP | 53 | 33.1% |
| R-CODOX-M/IVAC | 11 | 6.9% |
| R-hyperCVAD/MA | 6 | 3.8% |
| Other | 16 | 10.0% |
| Untreated | 4 | 2.5% |
| Unknown | 2 | 1.2% |
| Variable . | . | . |
|---|---|---|
| Age, median (range), y | 64 | 18-92 |
| Sex, n (%) | ||
| Male | 108 | 67.5% |
| Female | 52 | 32.5% |
| Poor PS, n (%)∗ | 33 | 20.6% |
| Stage, n (%)† | ||
| I or II | 48 | 30.6% |
| III or IV | 109 | 69.4% |
| Undetermined | 3 | |
| >1 extranodal site, n (%) | 66 | 41.3% |
| Bone marrow involvement, n (%)∗ | 39 | 24.4% |
| CNS involvement, n (%) | 11 | 6.9% |
| LDH > ULN, n (%)∗ | 110 | 68.8% |
| LDH > 3 × ULN, n (%)∗ | 37 | 23.1% |
| IPI, n (%) | ||
| Low | 34 | 21.3% |
| Intermediate low | 27 | 16.9% |
| Intermediate high | 42 | 26.3% |
| High | 44 | 27.5% |
| Undetermined | 13 | 8.1% |
| Morphology, n (%) | ||
| Burkitt-like | 72 | 45.0% |
| Blastoid | 38 | 23.8% |
| Unspecified | 50 | 31.3% |
| Cell of origin (based on IHC), n (%)† | ||
| GCB-like | 131 | 82.9% |
| Non-GCB | 27 | 17.1% |
| Undetermined | 2 | |
| CD10 expression, n (%) | ||
| Positive | 123 | 76.9% |
| Negative | 37 | 23.1% |
| BCL6 expression, n (%)† | ||
| Positive | 120 | 80.0% |
| Negative | 30 | 20.0% |
| Not tested | 10 | |
| BCL2 expression, n (%)† | ||
| Positive | 83 | 53.9% |
| Negative | 71 | 46.1% |
| Not tested | 6 | |
| MYC expression, n (%)† | ||
| Positive | 102 | 71.8% |
| Negative | 40 | 28.2% |
| Not tested | 18 | |
| MUM1 expression, n (%)† | ||
| Positive | 60 | 45.5% |
| Negative | 72 | 54.5% |
| Not tested | 28 | |
| Dual MYC and BCL2 expressor, n (%)† | ||
| Yes | 52 | 37.1% |
| No | 88 | 62.9% |
| Undetermined | 20 | |
| CD5 expression, n (%)† | ||
| Positive | 20 | 14.1% |
| Negative | 122 | 85.9% |
| Not tested | 18 | |
| MYC rearrangement, n (%) | ||
| Yes | 44 | 27.5% |
| No | 116 | 72.5% |
| BCL2 rearrangement, n (%)† | ||
| Yes | 17 | 12.7% |
| No | 117 | 87.3% |
| Not tested | 26 | |
| BCL6 rearrangement, n (%)† | ||
| Yes | 15 | 11.2% |
| No | 119 | 88.8% |
| Not tested | 26 | |
| First-line therapy, n (%) | ||
| DA-EPOCH-R | 68 | 42.5% |
| R-CHOP | 53 | 33.1% |
| R-CODOX-M/IVAC | 11 | 6.9% |
| R-hyperCVAD/MA | 6 | 3.8% |
| Other | 16 | 10.0% |
| Untreated | 4 | 2.5% |
| Unknown | 2 | 1.2% |